18F-FE-PE2I PET 在帕金森病中的定量与鉴别效能
本研究纳入9例早期帕金森病患者和34名健康志愿者,比较18F-FE-PE2I PET不同参考区与时间窗的定量偏差及鉴别效能,并与123I-FP-CIT扫描对比。结果显示18F-FE-PE2I鉴别早期PD与健康对照的准确率≥90%,效应量优于123I-FP-CIT,10分钟静态扫描诊断准确率非劣于临床常规123I-FP-CIT。
要点
- 18F-FE-PE2I PET鉴别早期PD与健康对照准确率≥90%,效应量优于123I-FP-CIT。
- [15-40]分钟窗对BPND的偏差最小,[50-60]分钟窗临床可行且鉴别力最佳。
- 枕叶皮层作为参考区较 cerebellum 时间稳定性更高、与BPND+1相关性更强、偏差更低。
核心结论
- 18F-FE-PE2I是适合体内DAT显像的放射性配体,对早期PD与健康对照有高鉴别力。
- 10分钟静态18F-FE-PE2I扫描的诊断准确率非劣于临床常规使用的123I-FP-CIT扫描。
研究设计与样本
- 研究纳入9例早期帕金森病患者(64.3±6.8岁,3名男性)和34名健康志愿者(47.7±16.8岁,13名男性)。
- 所有受试者接受60分钟动态18F-FE-PE2I PET-MR扫描,基于动态数据和MR勾画VOI计算BPND、半定量摄取比和SUVR。
- SUVR时间窗设为[15-40]分钟、[40-60]分钟和[50-60]分钟,参考区分别为枕叶皮层和小脑。
- 患者既往诊断流程中曾接受123I-FP-CIT扫描。
主要发现
- 以枕叶皮层为参考区时,SUVR相对BPND+1的偏差更小、相关性更高,且不受SUVR时间窗影响。
- [15-40]分钟窗偏差最小,与既往文献一致;晚期时间窗BPND+1与SUVR相关性略好。
- 联合PUT和CPR的SUVR判别分析在PD与HV间准确率≥90%,适用于两种参考区和所有研究时间窗。
- 患者半定量123I-FP-CIT与18F-FE-PE2I值及纹状体相对下降高度相关,18F-FE-PE2I在PUT和CPR SUVR上效应量更高。
关键数值与推荐
- PD与HV判别分析使用PUT和CPR的SUVR,准确率≥90%。
- SUVR时间窗评估包括[15-40]分钟、[40-60]分钟和[50-60]分钟。
- 参考区包括枕叶皮层和小脑。
临床怎么用
- 临床可考虑采用[50-60]分钟假平衡期10分钟静态18F-FE-PE2I PET扫描,兼顾可行性与鉴别力。
- 枕叶皮层可作为参考区首选,因其时间稳定性更高、与BPND+1相关性更强且偏差更低。
局限性
- 患者样本量较小(9例早期PD)。
- 未报告诊断准确率的置信区间及统计学非劣效检验细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Dopamine transporter (DAT) imaging is an important adjunct in the diagnostic workup of patients with Parkinsonism. 18F-FE-PE2I is a suitable PET radioligand for DAT quantification and imaging with good pharmacokinetics. The aim of this study was to determine a clinical optimal simplified reference tissue-based image acquisition protocol and to compare the discriminatory value and effect size for 18F-FE-PE2I to that for 123I-FP-CIT scan currently used in clinical practice. METHODS: Nine patients with early Parkinson's disease (PD, 64.3 ± 6.8 years, 3M), who had previously undergone a 123I-FP-CIT scan as part of their diagnostic workup, and 34 healthy volunteers (HV, 47.7 ± 16.8 years, 13M) underwent a 60-min dynamic 18F-FE-PE2I PET-MR scan on a GE Signa 3T PET-MR. Based on dynamic data and MR-based VOI delineation, BPND, semi-quantitative uptake ratio and SUVR[t1-t2] images were calculated using either occipital cortex or cerebellum as reference region. For start-and-end time of the SUVR interval, three time frames [t1-t2] were investigated: [15-40] min, [40-60] min, and [50-60] min postinjection. Data for putamen (PUT) and caudate nucleus-putamen ratio (CPR) were compared in terms of quantification bias versus BPND and discriminative power. RESULTS: Using occipital cortex as reference region resulted in smaller bias of SUVR with respect to BPND + 1 and higher correlation between SUVR and BPND + 1 compared with using cerebellum, irrespective of SUVR [t1-t2] interval. Smallest bias was observed with the [15-40]-min time window, in accordance with previous literature. The correlation between BPND + 1 and SUVR was slightly better for the late time windows. Discriminant analysis between PD and HV using both PUT and CPR SUVRs showed an accuracy of ≥ 90%, for both reference regions and all studied time windows. Semi-quantitative 123I-FP-CIT and 18F-FE-PE2I values and relative decrease in the striatum for patients were highly correlated, with a higher effect size for 18F-FE-PE2I for PUT and CPR SUVR. CONCLUSION: 18F-FE-PE2I is a suitable radioligand for in vivo DAT imaging with high discriminative power between early PD and healthy controls. Whereas a [15-40]-min window has lowest bias with respect to BPND, a [50-60]-min time window at pseudoequilibrium can be advocated in terms of clinical feasibility with optimal discriminative power. The occipital cortex may be slightly preferable as reference region because of the higher time stability, stronger correlation of SUVR with BPND + 1, and lower bias. Moreover, the data suggest that the diagnostic accuracy of a 10-min static 18F-FE-PE2I scan is non-inferior compared with 123I-FP-CIT scan used in standard clinical practice.
引用
- Delva A, Van Weehaeghe D, van Aalst J, et al. Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging. 2019. PMID: 31776633. doi:10.1007/s00259-019-04587-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。